Vaxcyte (PCVX) Receivables - Net (2021 - 2024)

Vaxcyte's (PCVX) quarterly Receivables - Net came in at $298000.0 in Q3 2024, down 84.2% year-on-year from $1.9 million in Q4 2023, and down 24.37% on a QoQ basis from $394000.0 in Q2 2024.

Vaxcyte (PCVX) Receivables - Net (2021 - 2024) Analysis & Trends

Vaxcyte (PCVX) has 4 years of Receivables - Net data on file, last reported at $298000.0 in Q3 2024.

  • On a quarterly basis, Receivables - Net fell 84.2% year-over-year to $298000.0 in Q3 2024; TTM through Sep 2024 was $298000.0, a 84.2% decrease from a year earlier, with the FY2023 full-year figure at $9000.0, down 99.13% from the prior year.
  • Receivables - Net for Q3 2024 stood at $298000.0, down from $394000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for PCVX reached as high as $5.0 million in Q3 2021 and fell as low as $9000.0 in Q4 2023.
  • Historically, Receivables - Net has averaged $1.2 million across 4 years, with a median of $394000.0 in 2024.
  • Across the five-year window, Receivables - Net sank 99.13% in 2023 and tumbled 84.2% in 2024, its largest moves.
  • Year by year, Receivables - Net stood at $5.0 million in 2021, then slumped by 79.42% to $1.0 million in 2022, then sank by 99.13% to $9000.0 in 2023, then surged by 3211.11% to $298000.0 in 2024.
  • Per Business Quant data, the three most recent Receivables - Net figures were $298000.0 in Q3 2024, $394000.0 in Q2 2024, and $127000.0 in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Vaxcyte 7.76 Bn 7.76 Bn -

Historic Data

Download Data
DateValue
Sep 30, 2024 298,000.00
Sep 30, 2024 298,000.00
Jun 30, 2024 394,000.00
Jun 30, 2024 394,000.00
Mar 31, 2024 127,000.00
Mar 31, 2024 127,000.00
Dec 31, 2023 9,000.00
Dec 31, 2023 9,000.00
Sep 30, 2023 1.89 Mn
Sep 30, 2023 1.89 Mn
Dec 31, 2022 1.03 Mn
Dec 31, 2022 1.03 Mn
Sep 30, 2021 5.00 Mn
Sep 30, 2021 5.00 Mn